RedHill Biopharma Announces Phase IIa 48-Week Final Results for RHB-104 in Multiple Sclerosis

RedHill Biopharma (NASDAQ:RDHL) (TASE:RDHL) today announces new data in its phase IIa trial investigating oral dose RHB-104 as a treatment for relapsing-remitting multiple sclerosis.
According to the press release:

“Top-line final (48 weeks) results are consistent with the previously announced interim results suggesting meaningful positive safety and clinical signals upon 24 weeks of treatment with RHB-104 as an add-on therapy and support further clinical development.”

Dr. Ira Kalfus, Medical Director of RedHill, said the following:

“Although designed as an exploratory proof-of-concept study in a very small patient population and not powered for efficacy, the study results demonstrate positive safety data and clinical signals, supporting additional studies to better investigate the therapeutic potential of RHB-104 in RRMS.”

Read the full press release here.